skip to content
  1. Home
  2. >
  3. Investment Q&A
You can view 3 more answers this month. Sign up for a free trial for unlimited access.

Investment Q&A

Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.

Q: Hi, I received shares in this company (HLS) via a reverse takeover of ADM (Automodular) back in late '17.
I don't see any other questions on this company thus the inquiry. What is your valued opinion of HLS?
From their web page...'HLS Therapeutics is a specialty pharmaceutical company focused on the acquisition and commercialization of late-stage development, commercial-stage promoted and established branded pharmaceutical products in the North American markets. We focus on products targeting the central nervous system and cardiovascular therapeutic areas. '
They seem to have a couple of drugs Vascepa, Clozaril and Absorica that are or will generate decent revenues going forward.
They also introduced a quarterly dividend recently and I know you favour companies when this occurs.
Are they a 'show me' story right now and patience is required for a couple quarters to see how they proceed, ie it looks like they will be filing for approval with Health Canada in early 2019 for Vascepa (it's already FDA approved).
Analysts targets are for around $20 for 2019 (from your 'Companies' page).

Cheers,
Steve
Read Answer Asked by Stephen on February 26, 2019
Q: Hi

I currently own GILD. Should I sell it and switch to BIIB or any other biotech. What are your thoughts about medical distribution companies (ABC, CAH, MCK) Which one would you recommend and any threat from Amazon. Should healthcare plans companies be part of healthcare portfolio and which one do you recommend.

Great service
Thanks
Ninad
Read Answer Asked by Ninad on February 26, 2019
Q: Hi 5i team,
Canadian financials account for 24% of our portfolio and 2% of this is in MFC in my TFSA account. I've held it for a number of years and I am up 50%. Presently, our total holdings are 60% Canada; 30% US and 10% International. I am thinking of selling MFC and replacing it with a US ETF or a fairly safe growth stock. I only have 1% in healthcare (split evenly between VHT and UNH in TFSA account) and am considering topping up based on MFC sale. Would appreciate your thoughts on this move. Thanks.
Read Answer Asked by Martha on February 22, 2019
Q: Hi, Recent pre release took many of us by surprise. We are reviewing our portfolio position in Savaria (Currently 3.75%). For a Balanced Growth and Income portfolio, you have indicated in a recent response, the right weighting as 2-2.5%. But, 5i Balanced portfolio has 4.24 % weight presently (reduced from 4.5 to 5% earlier due to price decline).
Is your response based on the recent pre announcment of their results ? Are you recommending that we reduce our holding to recommneded weight, all else being same as Balanced Portfolio ? If so, when do you plan to make the change?
Thanks
Read Answer Asked by rajeev on February 22, 2019
Q: Can you provide an update on RHT? It seems to have found a technical bottom since november and has made 3 successive higher lows as it moves up and down. What are the fundamentals like? How much of the fundamental strength that you initially saw still exists? Is this a dead (patient home monitoring type) company or just one that you lost patience with and could/should still go. I admit not to have looked into them beyond your recommendation so a summary of their potential catalysts and pitfalls over the next year would be amazing. Take a couple credits if needed to provide a full and thorough answer please.

Thanks
Read Answer Asked by Tim on February 21, 2019
Q: Is there a "reason " behind SIS announcing its preliminary and un audited year end and last quarter financial results suddenly , which it had never done in the past ? The figures were not that bad when compared to street estmates, though EBITDA was marginally lower . Is something "brewing " for SIS which an ordinary investor is unaware?
Read Answer Asked by Sriram on February 20, 2019
Q: What are your thoughts on SIS's premature earnings release with disappointing EBITDA miss and lowered guidance? Also they pointed to less acquisitions and more focusing on getting the house in order. Obviously not good to hear they are struggling in Europe. I have always liked this mgmt and I feel they handled this primarily negative release well and I appreciate their transparency and guidance on how they plan to fix the issues. But what does this mean for a company that has struggled for the last 5 months, are we now looking at another year plus of lowered guidance, less or no acquisitions, restructuring, and beaten down share price? Thanks
Read Answer Asked by Adam on February 20, 2019
Looking for more? Sign up for a FREE 14 day trial! No credit card required

We invite you to sign up for a 14 day free trial of 5i Research!
Experience all the benefits and tools we have to offer; stock research, model portfolios, Q&A with our experts, and so much more. Join a community of like-minded investors today!